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Abstract
Background: MicroRNAs (miRNAs) are short noncoding RNAs (approximately 22 nucleotides in length) that play
important roles in breast cancer progression by downregulating gene expression. The detailed mechanisms and
biological functions of miRNA molecules in breast carcinogenesis have yet to be fully elucidated. This study used
bioinformatics and experimental approaches to conduct detailed analysis of the dysregulated miRNAs, arm
selection preferences, 3’ end modifications, and position shifts in isoforms of miRNAs (isomiRs) in breast cancer.
Methods: Next-generation sequencing (NGS) data on breast cancer was obtained from the NCBI Sequence Read
Archive (SRA). The miRNA expression profiles and isomiRs in normal breast and breast tumor tissues were
determined by mapping the clean reads back to human miRNAs. Differences in miRNA expression and pre-miRNA
5p/3p arm usage between normal and breast tumor tissues were further investigated using stem-loop reverse
transcription and real-time polymerase chain reaction.
Results: The analysis identified and confirmed the aberrant expression of 22 miRNAs in breast cancer. Results from
pathway enrichment analysis further indicated that the aberrantly expressed miRNAs play important roles in breast
carcinogenesis by regulating the mitogen-activated protein kinase (MAPK) signaling pathway. Data also indicated
that the position shifts in isomiRs and 3’ end modifications were consistent in breast tumor and adjacent normal
tissues, and that 5p/3p arm usage of some miRNAs displayed significant preferences in breast cancer.
Conclusions: Expression pattern and arm selection of miRNAs are significantly varied in breast cancers through
analyzing NGS data and experimental approach. These miRNA candidates have high potential to play critical roles
in the progression of breast cancer and could potentially provide as targets for future therapy.
Background
Breast cancer is one of the major causes of cancer-related
deaths worldwide and the most common cancer among
women [1]. Metastatis to distant organs and lymph nodes
represents a major problem, usually leading to high mor-
tality. The investigation of breast cancer-associated genes
for early detection or therapeutic targeting could poten-
tially improve the survival rates of breast cancer patients.
MicroRNAs (miRNAs) are small RNA molecules with
important regulatory functions in several physiological
activities [2]. MicroRNAs are processed from primary
transcripts (pri-miRNAs) in 2 maturation steps. First, the
pri-miRNAs are processed by Drosha, forming the precur-
sor miRNAs (pre-miRNAs), composed of a 5p arm, a 3p
arm, and a terminal loop, approximately 70 nucleotides in
length. Following the transport of pre-miRNAs to the
cytoplasm by exportin 5, they are further processed by
Dicer to release the terminal loop and the duplex (5p arm/
3p arm), 22 nucleotides in length. The 5p arm/3p arm of
the duplex is unwound at the end because of weaker
hydrogen binding. The 5p or the 3p arm is selectively
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loaded into the RNA-induced silencing complex (RISC)
and serves as mature miRNA [3-5]. Recent studies
described a phenomenon in which RNA editing or nucleo-
tide addition generated 3’ end sequence variants of miR-
NAs [6-13]. Fernandez-Valverde et al. [6] reported
that miR-282 and miR-312a are enriched for 3’ adenosine
additions during early embryonic development, which
increases miRNA stability or enhances miRNA and
mRNA interaction.
MicroRNAs exert their effects by repressing their target
genes. They downregulate target gene expression by
repressing translation or by degrading mRNAs. Previous
studies reported that miRNAs play important roles in the
oncogenesis pathway [14-18]. The tumor-associated miR-
NAs were either tumor repressors, preferentially expressed
in normal tissue, or onco-miRNAs, preferentially expressed
in tumor tissue. These are aberrantly expressed in human
breast cancer, including miR-9, miR-21, miR-31, miR-34a,
miR-155, miR-200, miR-205, miR-206, and miR-335
[19-22]. Although several studies have investigated the
functions of miRNAs in breast tumors, these only included
a small fraction of existing miRNAs [23-26]. Using miRNA
profiling approach, numerous breast cancer-associated
miRNAs were identified [19,27-30]. Ryu et al. [27] identi-
fied 189 candidate novel microRNAs in human breast can-
cer cell lines by deep sequencing technology. Therefore,
emerging NGS technologies can be used not only to iden-
tify novel miRNAs, but can also be applied in several
miRNA-associated studies.
In the studies using NGS data for miRNA profiling, it is
usually observed that miRNA sequence reads exist as iso-
forms, named isomiRs, with position and length shift com-
pared with the reference miRNAs [31]. Recently, more and
more studies worked on the isomiR issues, such as isomiR
pattern preferences in specific libraries, target gene selec-
tion difference between different isomiRs and so on [6,32].
Therefore, NGS data provides a good resource for miRNA
expression profiling and isomiR related studies. In 2011,
Farazi et al., [33] used NGS data to determine miRNA
expression profiles in breast tissues with differing tumor
malignancies. They focused on the relevance of specific
miRNAs and the tumor malignancy type, without provid-
ing further experimental validation. The present study
applied their NGS data to conduct analysis of miRNA-
associated changes in breast cancer, including differential
miRNA expression, position shifts in isomiRs, 3’ end mod-
ifications, and arm selection preferences of pre-miRNAs.
Materials and methods
Collection and preprocessing of sequence reads
The small RNA transcriptome data of breast tumor
(accession number: SRP006574) was downloaded from
the NCBI Sequence Read Archive (SRA). These data
included more than 200 samples and was classified into 2
libraries: normal and tumor (invasive ductal carcinoma).
The initial sequence reads were subjected to 3’ adaptor
trimming to generate the clean reads, as described pre-
viously [10,13]. For higher confidence, only the clean
reads with read count ≥ 2 were included in further
analysis.
Mapping clean reads to pre-miRNAs
MicroRNA expression profiles in different libraries were
determined by mapping the clean reads back to human
pre-miRNAs (miRBase 17). Several miRNA genes show
high similarity (such as 68 mir-548 paralogous miRNAs in
humans). This results in multiple ambiguous hits when
mapping a read back to human miRNAs if variations are
allowed. To eliminate the ambiguous mapping hits, no
mismatch was allowed during the mapping procedure.
Previous reports described observing nucleotide additions
at the 3’ ends of miRNAs [31,34-36] that could cause mis-
matches at the terminal of the mapping alignment. In
order to follow the no-mismatch policy and keep the 3’
end variation, like the method in Fernandez-Valverde’s
study [6], we trimmed out the terminal 3’ end mismatch
one by one until the perfect match reads were at least 18
nucleotides in length. By doing so, we can keep not only
an at least 18-nt perfect alignment but also the 3’ end
variations.
Classifying non-miRNA reads into different data sets
The non-miRNA sequence reads were further classified
into 9 classes by mapping to different data sets with bow-
tie [37], allowing a single nucleotide variation. The
sequences of mRNAs and other ncRNAs were derived
from NCBI RefSeq 47 [38]. The sequences of tRNAs was
downloaded from the Genomic tRNA database [39];
sequences of rRNAs were downloaded from the SILVA
database [40]. The sequences of snoRNAs, scaRNAs, and
snRNAs were all downloaded from NONCODE [41]. The
sequence reads not belonging to any of the described
RNA classes were uploaded to RepeatMasker for identifi-
cation of repeat elements and classified as unknown.
Samples and RNA extraction
Ten paired (tumor and adjacent normal) samples were
collected from breast cancer patients receiving surgical
operation at the Department of Surgery, Kaohsiung Veter-
ans General Hospital. The total RNA of tissue was
extracted using a TRIzol reagent (Invitrogen, USA),
according to the instruction manual. Briefly, tissue samples
were homogenized in 1 ml of TRIzol reagent and mixed
with 0.2 ml chloroform to extract protein; RNA was preci-
pitated using 0.5 ml isopropanol. The concentration, pur-
ity, and amount of total RNA were determined using a
Nanodrop 1000 spectrophotometer (Nanodrop Technolo-
gies Inc., USA).
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Stem-loop reverse transcription (RT) and real-time PCR
Reverse transcription primers were specifically designed
for the examined miRNAs according to the methods
reported by Chen et al., [42]. One microgram of total
RNA was reverse transcribed in a stem-loop RT reaction
with RT primers and SuperScript III Reverse Transcriptase
according to the user’s manual (Invitrogen, Carlsbad, CA,
USA). The reaction was performed under the following
incubation conditions: 30 min at 16°C, followed by
50 cycles of 20°C for 30 s, 42°C for 30 s, and 50°C for 1 s.
The enzyme was subsequently inactivated by incubating at
85°C for 5 min. Real-time PCR reactions were performed
using an miRNA-specific forward primer and a universal
reverse primer with incubation at 94°C for 10 min, fol-
lowed by 40 cycles of 94°C for 15s and 60°C for 32 s. Gene
expression levels were detected using SYBR Green I assay
(Applied Biosystems, Foster City, CA, USA), and miRNA
expression levels were normalized to that of U6. The pri-
mer sequences for the examined miRNAs are listed in
Additional File 1.
Pathway enrichment analysis
Human miRNA target gene data was downloaded from
TargetScan 6.0. The target genes of differentially expressed
miRNAs were extracted, then mapped onto KEGG path-
ways based on the enzyme commission (EC) numbers
using the R package SubPathwayMiner v.3.1 [43]. The
hypergeometric test was then performed to identify signifi-
cantly enriched pathways and calculate the false positive
discovery rate in FDR-corrected q-value.
Results and discussion
Analysis of miRNA sequence reads
After subjecting the downloaded small RNA reads to the
3’ adaptor trimming procedure, the normal library con-
tained approximately 2.7 million clean reads and the
tumor library approximately 38.3 million clean reads
(Table 1). Using the mapping criteria, the clean reads were
mapped back to human pre-miRNAs (miRBase 17).
Approximately 75% of the normal clean reads and 85% of
the tumor clean reads belonged to miRNAs. The detection
of a greater number of miRNA and pre-miRNAs in the
tumor library than in the normal library reflected greater
sequencing depth in the tumor library. The libraries con-
tained an unequal number of initially used reads; there-
fore, comparisons in miRNA expression between the
libraries were performed using the unit of transcript per
million (TPM). There were no significant differences in
the expression levels of most miRNAs between normal
and tumor tissues (Additional File 2).
The clean reads not defined as miRNAs were further
classified into an additional 9 classes by mapping to other
transcript sequences. As shown in Table 2, in most cate-
gories, the clean read distributions in the 2 libraries were
similar. However, compared with the normal library, the
tumor library had a higher percentage of miRNA reads
but lower percentages of other ncRNA and unknown
reads. After further investigation, more than 85% of the
unknown category (data not shown) in the 2 libraries
could not be mapped back to the human genome (hg19).
Our previous study showed that such unmappable reads
could be derived from the exon-exon junctions of novel
alternative splicing transcripts or from the transcripts of
infection viruses [44]. These unmappable reads warrant
further investigation.
Differentially expressed miRNAs
A comparison of the miRNA expression levels in normal
and tumor breast tissues provided a list of differentially
expressed miRNAs. Similar to other high throughput
technologies, NGS data is susceptible to background
noise, producing biased results. Stem-loop RT-PCR was
thus used to further validate the 23 miRNAs with the
highest fold changes in expression levels between normal
breast and breast tumor tissues. Stem-loop RT-PCR
reportedly shows a high correlation with NGS technolo-
gies [10,45]. In common with RT-PCR assays, an internal
control is used for comparing the same genes in different
samples. In NGS assays, no such internal control is used.
The fold changes in the same miRNAs between normal
and tumor breast tissues, as detected using PCR and
NGS, were thus compared. Among the 23 evaluated miR-
NAs, the fold changes detected using PCR and NGS were
highly correlated, with a Pearson correlation coefficient
of 0.89 (Figure 1). This was a similar finding to those of
previous studies.
Among the 23 examined miRNAs, 15 are preferentially
expressed in normal tissue, whereas 8 are preferentially
expressed in tumor tissue (Table 3). The tissue prefer-
ences of miRNAs determined using NGS are consistent
with those identified using PCR with only one exception:
hsa-miR-423-3p. The present study, therefore, generated
an authentic list of differentially expressed miRNAs in
breast cancer using an experimental approach.
Table 1 Categories of sequence reads in the 2 breast
libraries.
Library Normal Tumor
# clean reads 2 785 848 38 335 412
% miRNA reads 75.24% 84.79%
# detected pre-miRNAs 455 689
# detected miRNAs 631 906
# detected miRNAs at opposite arm 54 150
% miRNA reads with 3’ end modification 17.65% 12.45%
According to miRBase 17 annotation, there are 1424 human pre-miRNAs,
encoding 1733 mature miRNAs. These pre-miRNAs and mature miRNAs result
in 1902 pairs of pre-miRNA/miRNA.
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Enrichment analysis of miRNA-involved pathway
Following the identification of the differentially expressed
miRNAs, the subsequent stage was to identify their func-
tions as defined by their target genes. Several computa-
tional methods can be used to identify the putative target
genes of miRNAs [46-49]. However, these computational
methods typically depend on the hydrodynamic stability
of the miRNA/3’UTR duplex, and usually produce several
false positive results. The most recently developed
method is dependent on computational identification
and also on the enrichment analysis of a target gene
pathway [50]. The present study applied the same strat-
egy and did the analysis on the miRNAs with the follow-
ing features: with high expression alteration and high
expression level in at least one library. So, we selected the
union of the target genes of hsa-miR-141 and hsa-miR-
200b for tumor-preferring miRNAs, and the union of the
target genes of hsa-miR-22, hsa-miR-125b, and hsa-miR-
99a for normal-preferring miRNAs. The 2 unions of
genes were individually subjected to pathway enrichment
analysis. The pathway enrichment analysis result showed
that the target genes of tumor-preferring miRNAs are
significantly enriched in the mitogen-activated protein
kinase (MAPK) pathway, with a p-value of 2.1E-6 (Addi-
tional file 3); while, the target genes of normal-preferring
miRNAs are significantly enriched also in the mitogen-
activated protein kinase (MAPK) pathway, with a p-value
of 2.4E-6 (Additional file 4).
The MAPK pathways are highly conserved kinase mod-
ules involved in fundamental cellular processes such as
growth, proliferation, migration, and apoptosis [51].
Studies have identified that the miR-200 family (miR-200a,
miR-200b, miR-200c, miR-141 and miR-429) is overex-
pressed in breast cancer, promoting breast cancer metasta-
sis and drug resistance [25,52]. Studies have also reported
that overexpression of miR-200 in epithelial cell lines leads
to an inhibition of transforming growth factor-b (TGF-b)
and induction of epithelial mesenchymal transition (EMT)
[53,54]. These results indicated that the miR-200 family
plays dual roles in modulating breast cancer metastasis
through the regulation of the complex MAPK signaling
pathway. However, miR-99a plays opposite roles in the
Table 2 Categories of clean sequence reads in the 2 breast libraries
Category miRNA mRNA tRNA rRNA snoRNA scaRNA snRNA other ncRNA repeat unknown
Normal 75.24% 2.16% 0.47% 0.87% 0.84% 0.04% 0.12% 9.78% 0.0349% 10.45%



















Figure 1 Comparison of fold changes in expression determined using NGS analysis and PCR. The scatter plot shows that NGS and PCR
results were highly correlated, with a Pearson correlation coefficient of 0.89
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regulation of cancer progression. Oneyama et al. [55]
reported that overexpression of miR-99a led to the sup-
pression c-Src-transformed cell growth, by controlling the
mTOR/FGFR3 pathway in various human cancers. In
epithelial NMUMG cells, however, miR-99a promoted
proliferation and migration by regulating TGF-b-induced
breast EMT [56]. Imbalance in the MAPK signaling path-
way can, therefore, lead to promotion or inhibition of can-
cer cell progression. This data indicates that aberrant
miRNA expression can result in the dysregulation of
breast cancer cell proliferation, apoptosis, cell cycle, and
migration through regulation of the component genes of
the complex MAPK signaling pathway.
Previous studies usually focus on the regulation relation-
ship between one miRNA versus one pathway. Since many
miRNAs are simultaneous up- or down-regulation in the
same tissue, we are curious if they simultaneously act on
the same pathway. So, we pick up the target gene unions
of up- or down-regulated miRNAs, followed by pathway
enrichment analysis on the target genes of the same
union. Our result showed that the simultaneously up-
regulated or down-regulated miRNAs execute their func-
tions by acting on the same MAPK pathway. Actually, we
also did the pathway enrichment analysis as usual, one
miRNA versus one pathway. And, we got the same con-
clusion that the simultaneously up- or down-regulated
miRNAs simultaneously act on the same pathway.
MicroRNA 3’ end additional nontemplate nucleotides in
breast cancer
MicroRNAs reportedly undergo RNA editing or nucleo-
tide addition at the 3’ end, causing a mismatch at the ter-
mini of the mapping alignments [31,34-36]. As shown in
Figure 2, the isomiRs of miR-511 have adenine (A) or ura-
cil (U) added at their 3’ ends. Therefore, the 3’ end addi-
tional nontemplate nucleotides widely occur during the
miRNA maturation process. Further investigation of the 3’
end nucleotide modification events using the alternative
mapping procedure showed that more than 12% of
miRNA reads undergo 3’ end nucleotide modification in
all libraries (Table 1). As shown in Additional File 5, A
and U accounted for approximately 80% of modification
events. In addition, AA, UU, AU, cytosine (C), and gua-
nine (G) contributed at least 1% of 3’ end nucleotide mod-
ification events. The 3’ end nucleotide modification event,
therefore, prefers the A or U nucleotide. The same nucleo-
tide modification preferences were displayed by normal
breast and breast tumor tissues.
Table 3 Validation of differentially expressed miRNAs using PCR.
miRNA NGS normal NGS tumor NGS fc PCR fc Consistent?
has-let-7b 32 594.1 16 107.1 0.49 0.46 Y
hsa-let-7c 7 710.1 2 439.1 0.32 0.44 Y
hsa-miR-22 69 532.1 24 576.1 0.35 0.24 Y
hsa-miR-125b 44 624.1 6 613.1 0.15 0.37 Y
hsa-miR-143 38 419.1 17 359.1 0.45 0.14 Y
hsa-miR-144 3 548.1 351.1 0.10 0.30 Y
hsa-miR-145 28 682.1 6 435.1 0.22 0.26 Y
hsa-miR-193a-5p 1 836.1 298.1 0.16 0.27 Y
hsa-miR-193b 2 469.1 1 058.1 0.43 0.30 Y
hsa-miR-199b-5p 1 608.1 1 055.1 0.66 0.83 Y
hsa-miR-320a 16 734.1 3 060.1 0.18 0.75 Y
hsa-miR-378 12 610.1 1 542.1 0.12 0.24 Y
hsa-miR-497 8 005.1 2 010.1 0.25 0.29 Y
hsa-miR-99a 31 360.1 5 548.1 0.18 0.16 Y
hsa-miR-141 5007.1 14 541.1 2.90 5.88 Y
hsa-miR-375 240.1 2 372.1 9.88 37.95 Y
hsa-miR-425 592.1 2 529.1 4.27 1.93 Y
hsa-miR-203 197.1 1 045.1 5.30 9.80 Y
hsa-miR-342-3p 350.1 1 331.1 3.80 3.43 Y
hsa-miR-182 316.1 1 653.1 5.23 11.86 Y
hsa-miR-200b 1 362.1 4 162.1 3.06 12.61 Y
hsa-miR-183 118.1 1 067.1 9.04 6.12 Y
hsa-miR-423-3p 2 446.1 1 993.1 0.81 5.96 N
NGS normal and NGS tumor denote miRNA relative read counts (TPM) in normal and tumor tissues. The NGS fold change (NGS fc) values are the quotients of
miRNA read counts in normal tissue divided by those in tumor tissue. The PCR fold change (PCR fc) values are the quotients of miRNA expression levels, relative
to U6 in normal tissue, divided by those in tumor tissue, averaged from 4 independent experiments
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Position shifts in isomiRs in breast cancer
It has been widely observed that miRNA exists as iso-
forms, or isomiRs, generated by a position shift during the
maturation process [31]. The present study detected all
isomiRs by mapping the clean reads back to pre-miRNAs.
For example, hsa-miR-511 has 5 isomiRs, each with differ-
ing length. The expression of an miRNA can be derived by
summarizing the read counts of its isomiRs (Figure 2).
Morin et al. [31] showed that the miRBase reference
miRNA (the isomiR with position shift 0,0 in Figure 2) is
not always the most abundant isomiR. Among the
detected miRNAs in libraries, approximately 55% are the
most abundant isomiRs; most of the remaining miRNAs
are the second or third most abundant isomiRs.
Although highly expressed miRNAs tend to have more
isomiR types, the isomiR distribution between different
libraries can differ [10,13], indicating their diverse regula-
tory roles. The present study’s data showed that position
shifts occurred more frequently at the 3’ end of miRNAs.
Detailed analysis of the position shifts in miRNAs at both
ends revealed that the 2 libraries displayed similar patterns
in position shift (Figure 3). At the 5’ end, position shift “0”
dominated, contributing 95% of all miRNA reads; position
shift “-1” and “1” accounted for only 1% and 4% of miRNA
reads. At the 3’ end, position shift “0” contributed 56% of
all miRNA reads, remaining dominant. Other position
shifts “-2,” “-1,” “1,” and “2” accounted for 5%, 20%, 15%,
and 1% of miRNA reads, respectively. In summary, most
isomiRs displayed higher frequency position shifts at their
3’ end during the miRNA maturation procedure. Addi-
tional file 6 displays the overall mapping results of the
miRNAs of all libraries.
Arm selection preferences in breast cancer
According to miRBase annotation, several pre-miRNAs
encode mature miRNAs at both arms; however, several
encode mature miRNAs at only one arm. With increasing
NGS sequencing depth, additional miRNAs can be
detected at the opposite arms of the pre-miRNAs, origin-
ally annotated to encode mature miRNAs at only one
arm [10,13]. This phenomenon was observed by mapping
the clean reads back to pre-miRNAs (Table 1). Figure 2
presents one case in which hsa-miR-511-1 was annotated
to encode mature miRNA at its 5p arm according to
miRBase 17. However, additional miRNA was detected at
its 3p arm. The newly detected 3p miRNA displayed
higher expression levels than the original 5p miRNA.
Squadrito et al. [57] reported that miR-511-3p is the
major active strand of miR-511 in tumor-associated
macrophages. In NGS analysis, results showed a higher
abundance of miR-511-3p than miR-511-5p in breast
cancer cells. To further investigate regulation of 5p and
3p arm selection of pre-miRNAs during breast cancer
progression, the pre-miRNAs annotated to encode
mature miRNAs at both arms were selected and their
ratios of 5p arm to 3p arm expression were further com-
pared in normal breast and breast tumor tissues. Based
on hydrogen bonding theory, the selection preference
Figure 2 Mapping results of hsa-miR-511-1. As shown in 5p:16-36, hsa-miR-511-1 encodes mature miRNA at its 5p arm only and miRNA
spans from nucleotide 16 to 36 of the hairpin. The integer values on the left denote the read count of each isomiR. The comma-separated
values denote the position shift in the isomiR relative to the miRBase annotated positions (16 to 36). The nucleotides in lowercase denote the
sequence fragments originating from the 3’ modification event (Additional file 5)
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between the 5p arm and 3p arm of pre-miRNA is an
intrinsic characteristic of pre-miRNA. Data indicated that
most of the examined pre-miRNAs were compatible with
this theory, and the selection preferences of the 5p and
3p arms were consistent in normal and tumor tissues. In
17 of the pre-miRNAs, 5p/3p selection preference was
not always consistent during breast cancer progression
(Table 4). Stem-loop real-time PCR was used to further
examine the expression of the 5p arm and 3p arm miR-
NAs of miR-324 and miR-455 in 10 paired (tumor and
adjacent normal) breast cancer tissue samples. In Figure 4,
the NGS data showed that the expression ratios of the 5p
arm to 3p arm miRNAs of miR-324 and miR-455 were
individually increased and decreased in the tumor, respec-
tively, compared with in normal tissue. The 10 paired tis-
sue samples provided consistent results. The ratio of 5p to
3p expression in miR-324 was increased significantly in
breast cancer cells. These results showed that the miRNAs
of samples did not display 5p or 3p preference consis-
tently, suggesting the existence of another regulatory
mechanism. This issue warrants further investigation.
Conclusions
The present study performed a series of sequence analy-
sis to evaluate miRNA-associated changes in breast can-
cer, including miRNA expression, arm selection, 3’ end
a b
Figure 3 Position shifts at the 5’ end and 3’ end of miRNA reads. The position shifts at the miRNA 5’ end and 3’ end can be measured by
comparing with the location of the miRBase reference miRNAs. (a) The position shift at the 5’ end is less diverse and highly dominated by “0";
(b) the position shift at the 3’ end is more diverse
Table 4 Arm selection preference of 5p arm and 3p arm miRNAs in normal breast and breast tumor tissues.
pre-miRNA Location N5p N3p T5p T3p
hsa-miR-214 mi:30-51; MA:71-92 88 226 133 171
hsa-miR-576 5p:16-37; 3p:55-76 7 44 19 17
hsa-miR-154 MA:15-36; mi:51-72 21 8 7 14
hsa-miR-193a 5p:21-42; 3p:55-76 1 836 1 127 488 2 384
hsa-miR-296 5p:14-34; 3p:48-69 24 34 8 4
hsa-miR-361 5p:6-27; 3p:45-67 105 215 1 043 310
hsa-miR-324 5p:16-38; 3p:53-72 233 341 317 91
hsa-miR-339 5p:15-37; 3p:50-72 215 217 298 194
hsa-miR-493 mi:16-37; MA:57-78 2 5 22 9
hsa-miR-455 5p:16-37; 3p:54-74 99 72 107 308
hsa-miR-664 mi:11-34; MA:49-71 58 8 21 87
hsa-miR-212 3pM:71-91 22 7 7 6
hsa-miR-142 5p:16-36; 3p:52-74 914 1 102 8 661 10 074
hsa-miR-362 5p:5-28; 3p:42-63 174 34 145 114
hsa-miR-376a-1 mi:7-28; MA:44-64 41 24 9 13
hsa-miR-382 5pM:11-32 217 23 51 30
hsa-miR-151 5p:11-31; 3p:47-67 946 1 249 2 721 3 109
N5p, N3p, T5p, and T3p denote miRNA relative read counts (TPM) of 5p arm and 3p arm in normal and tumor tissues
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modifications, and position shifts in isomiRs. We identi-
fied 22 differentially expressed miRNAs in normal breast
and breast tumor tissue that might be involved in breast
cancer progression through regulation of MAPK signal-
ing. MicroRNAs widely displayed 3’ end modifications
and position shifts in isomiRs in breast cancer. However,
no significant differences emerged between normal
breast and breast tumor tissue during carcinogenesis.
Arm usage of some miRNAs displayed significant pre-
ferences in breast cancer, suggesting that hydrogen
bonding theory does not sufficiently explain 5p or 3p
arm selection during carcinogenesis. Further investiga-
tion of the possible effects of arm selection of miRNAs
on breast carcinogenesis is needed. The present study’s
findings provide insights into breast cancer that might




Figure 4 The 5p/3p arm selection of miR-324 and miR-455 in 10 breast cancer patients. (A) Ratios of 5p and 3p arms of miR-324 and miR-
455 as observed from NGS data. (B) and (C) Ratios of 5p and 3p arms of miR-324 and miR-455 in the breast cancer tissues of 10 patients as
evaluated using stem-loop quantitative PCR (left panels). Ratios of 5p and 3p arm usage are indicated in the boxplots in the right panels. All
samples were assessed in triplicate and analyzed using Student’s t test (p < 0.05 was considered significant)
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Additional material
Additional file 1: Sequences of primers for miRNA detection
Additional file 2: Expression levels in normal and tumor tissues.
Additional file 3: The enriched pathway of the target gene union of
hsa-miR-141 and hsa-miR-200b (tumor-preferring). The target genes
of hsa-miR-141 and hsa-miR-200b were significantly enriched in the
MAPK pathway (p = 2.1E-6). The target genes are labeled in red
Additional file 4: The enriched pathway of the target gene union of
hsa-miR-22, hsa-miR-125b, and hsa-miR-99a (normal-preferring). The
target genes of hsa-miR-22, hsa-miR-125b, and hsa-miR-99a were
significantly enriched in the MAPK pathway (p = 2.4E-6). The target
genes are labeled in red.
Additional file 5: Distribution of 3’ end modifications. Using the
alternative mapping procedure, the 3’ end modification events were
quantified. In this figure, only the modification events more than 1% in
all libraries are illustrated
Additional file 6: Mapping information of miRNA reads to pre-
miRNAs in all libraries.
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